Parallaxis Insights: AUST L Evidence Requirements: How Much Is "Enough" Depends on the Claim

29 Jun 2026

min read

Quick answer — For Australian Listed Medicines (AUST L), the TGA's Evidence Guidelines v4.0 map the evidence required directly to the type and specificity of the indication selected. Non-specific traditional use indications carry the lowest threshold; specific scientific indications require well-designed human studies matched to the product's dose and population; establishment claims such as "clinically proven" sit outside the AUST L framework entirely and are governed by the Therapeutic Goods Advertising Code. Across TGA, FTC, and ACCC frameworks the pattern is consistent: the more specific the claimed outcome, the higher the evidence bar, and most substantiation failures happen in the gap between the claim a brand wants to make and the evidence it actually holds.

Most brands approach the substantiation question the wrong way around. They start with the evidence they have, then look for a claim it supports. Or they start with the claim they want to make, commission one study, and assume that settles it. Neither approach reliably produces a defensible position, because the substantiation threshold is not a fixed bar — it moves with the claim. Understanding how it moves, and what drives it up or down, is the foundational skill in claims strategy.

Why the Threshold Moves With the Claim

The type of substantiation needed for a claim depends on many factors, including the product being marketed and the nature of the claim. That principle comes directly from the FTC's Health Products Compliance Guidance, and it applies equally across TGA and ACCC frameworks. There is no fixed number of studies. There is no universal study design that guarantees substantiation. What there is, across every jurisdiction, is a question: does the evidence you hold adequately support the specific message a reasonable consumer would take from this claim?

Five factors consistently drive the threshold up or down across frameworks.

Specificity of the claimed outcome. "Supports general wellbeing" requires less evidence than "supports cardiovascular health," which requires less than "clinically proven to reduce LDL cholesterol." As the claim becomes more specific — naming a body system, a measurable outcome, a timeframe, or a population — the evidence required becomes more specific in parallel.

Consequence of a false claim. Claims that, if unfounded, could present a substantial risk of injury to consumer health or safety will be held to a higher level of scientific proof. A claim that could lead a consumer to delay seeking medical treatment, or to self-manage a serious condition, carries a higher threshold than a claim about general vitality.

Type of claim being made. General wellbeing claims, structure/function claims, traditional use claims, and establishment claims each operate under different frameworks and carry different evidence requirements. The NARB's May 2026 ruling on Tru Niagen confirmed that the required substantiation depends on the message conveyed to consumers, not the advertiser's regulatory classification. A brand cannot label a claim "structure/function" to access a lower evidence standard if the consumer takes away a stronger message.

Surrounding context. The claim does not exist in isolation. Imagery, testimonials, product names, and surrounding marketing copy all contribute to the net consumer impression. Evidence that supports a carefully scoped claim may not support the same claim placed next to lifestyle imagery implying perceptible health improvements.

Totality of the existing evidence. Studies relied on by an advertiser should be largely consistent with the surrounding body of evidence. Wide variations in outcomes and inconsistent or conflicting results raise serious questions about the adequacy of substantiation. Holding one well-designed study for a claim is weaker if ten other studies in the field show the opposite.

The AUST L Framework: Four Evidence Levels Mapped to Claim Type

For brands selling supplements in Australia, the TGA's Evidence Guidelines for Listed Medicines (v4.0, released November 2024) provide the most structured framework available for matching evidence to claim type. An AUST L listing — the designation for low-risk listed medicines on the Australian Register of Therapeutic Goods — does not require pre-market efficacy assessment by the TGA. But it does require the sponsor to hold adequate evidence supporting every indication at the time of listing, and to produce that evidence promptly if the TGA requests it in a compliance review.

Indications for listed medicines are either traditional or scientific, and both are further classified into non-specific or specific sub-types depending on how the indication is phrased. The sub-type determines the minimum evidence level required. Getting that classification right at the outset — before the ARTG entry is submitted — is where the real compliance work happens.

The TGA's Evidence Guidelines v4.0 describe a five-step process for compiling an AUST L evidence package: find the evidence through systematic or non-systematic literature search, assess its relevance and quality, select the indications the evidence supports, document findings in a critical appraisal format, and submit the complete package if the TGA requests it in a compliance review. Getting that sequence right — particularly the alignment between indication selection and the evidence actually found and assessed — is where most AUST L substantiation problems originate.

Non-specific traditional indications sit at the lowest end of the evidence spectrum. These cover general health and wellbeing claims supported by evidence of traditional use — for example, "traditionally used in Western herbal medicine to support digestive health." For some non-specific indications relating to health maintenance, a systematic literature search may not be necessary and a non-systematic search can be used. The evidence requirement is real but relatively modest: documentation of traditional use within a recognised paradigm, applied to an ingredient sufficiently identical to the one described in that evidence.

Non-specific scientific indications cover general health maintenance claims supported by scientific evidence. "Maintains general health and wellbeing" or a general biomarker indication — supporting normal iron levels in healthy adults, for example — fall into this category. Well-conducted observational studies or cohort data can support these indications, though RCT-level evidence strengthens the position. General biomarker permitted indications are classified as non-specific, which is a point many brands miss when they assume any biomarker claim automatically requires a clinical trial.

Specific scientific indications cover claims that name a particular physiological outcome, body system, or population. "Supports healthy cardiovascular function" or "helps maintain cognitive function in adults over 50" are specific scientific indications. At this level, the evidence expectation escalates significantly. The TGA expects human studies directly applicable to the specific indication, at a relevant dose, in a population representative of the target consumer. Whether using traditional or scientific indications, the specificity of your indication determines the level of evidence required.

Establishment claims sit outside the AUST L listed medicines framework entirely — making them the highest-risk category for Australian brands. A claim that a product is "clinically proven" to produce a specific outcome is not a permitted indication in the ARTG. It is an advertising claim, governed by the Therapeutic Goods Advertising Code and subject to the ACCC's misleading conduct provisions under Australian Consumer Law. The evidence standard for such a claim mirrors the FTC's standard for US brands: well-designed human clinical trials, in a population representative of the target consumer, measuring outcomes consistent with the consumer impression created by the claim.

The most common AUST L substantiation problem is not that brands lack evidence entirely — it is that the evidence they hold maps to a different indication level than the one they have selected. A product with good traditional use documentation listed under a specific scientific indication, or a product with a single small observational study attempting to support a specific physiological claim, are both carrying substantiation gaps that a TGA compliance review will identify.

If you are not sure whether the evidence you hold matches the indications on your current ARTG entry, the AUST L Evidence Readiness Assessment at assess.parallaxis.com.au gives you a structured starting point in under five minutes.

The FTC Framework: What "Competent and Reliable Scientific Evidence" Actually Means

For brands with US market exposure, the FTC's substantiation standard for health claims is competent and reliable scientific evidence — a phrase that sounds precise but contains significant practical complexity. The FTC has defined that standard as tests, analyses, research, or studies conducted in an objective manner by experts in the relevant disease, condition, or function to which the representation relates, and generally accepted in the profession to yield accurate and reliable results.

What that means in practice depends on the claim. As a general matter, substantiation of health-related benefits will need to be in the form of randomised, controlled human clinical testing to meet the competent and reliable scientific standard. But the FTC is explicit that quality matters more than quantity: a well-designed single study carries more weight than multiple poorly designed ones.

Four specific positions from the FTC's guidance are worth understanding precisely.

Animal and in vitro studies cannot, on their own, substantiate a health claim. They may be part of a broader evidence package, but they do not replace human clinical evidence for a claim directed at human consumers.

Consumer testimonials do not substantiate a claim. The FTC treats testimonials as if the brand were making the claim directly. A testimonial reporting results not typical of the general consumer population requires disclosure of what results consumers can actually expect — and even with that disclosure, the underlying claim still needs independent scientific evidence.

Statistical significance is not the same as clinical meaningfulness. Any statistically significant results must translate to a benefit that is clinically meaningful for consumers. Some results that are statistically significant may be too small to provide real consequences for consumer health.

Traditional use does not substitute for scientific evidence in the US. Under FTC law, claims for products based on traditional use are subject to the same requirement of substantiation in the form of competent and reliable scientific evidence as any other product. This is a significant point of divergence from the TGA's AUST L framework, where traditional use is an accepted substantiation pathway. Brands selling into both Australia and the US need to navigate that difference explicitly.

Where Most AUST L Brands Get This Wrong

Three patterns account for the majority of AUST L substantiation problems in practice.

Ingredient evidence standing in for product evidence. A study demonstrating that an ingredient has a particular effect, at a dose, in a particular population, does not automatically substantiate a claim on a commercial product containing that ingredient at a different dose in a different formulation. The evidence must map to the product as it actually exists — including its dose, matrix, and the population it is marketed to. Ingredient supplier dossiers are a valuable starting point for building an AUST L evidence pack, but they are not a finished evidence package. The TGA assesses whether the evidence maps to the specific product as listed, not to the ingredient category in general.

Biomarker outcomes presented as consumer-perceptible outcomes. Evidence that a product raises a biomarker — NAD+ levels, serum vitamin D, ferritin levels — does not automatically substantiate a claim that the product improves how a consumer feels or functions. The relationship between the biomarker and the consumer-relevant outcome needs to be separately established, or the claim needs to be scoped to the biomarker rather than the downstream outcome. Under the AUST L framework, general biomarker indications are classified as non-specific — which means a brand using biomarker language to imply a specific functional benefit is likely operating at a higher evidence level than it realises.

Claim language that outpaces the evidence through context. A carefully worded structure/function claim can become an establishment claim in context. Placing "supports healthy energy metabolism" next to before-and-after testimonials, imagery of people performing at peak, and a product name suggesting dramatic vitality creates a net consumer impression that the structure/function language alone does not. The TGA, ACCC, and FTC all assess the full advertising context, not the literal wording of the claim in isolation. An AUST L listing with appropriate indications does not provide cover for advertising that makes stronger implied claims than the evidence supports.

A Practical Framework for Matching Evidence to AUST L Claims

Before any claim goes to market, two questions structure the substantiation assessment.

The first is: what is the strongest message a reasonable consumer would take from this claim, in this context? Not the message the brand intends, but the message the evidence must support. If the answer is more specific, more outcome-focused, or more establishment-sounding than the brand realises, the evidence bar is higher than assumed.

The second is: does the evidence held — at this product's dose, in this population, measuring this product's relevant outcomes — support that message? Not the ingredient category, not the mechanism, not analogous products at different doses. This product, this claim, this evidence.

For AUST L sponsors specifically, a third question applies: does the indication selected in the ARTG entry accurately reflect the evidence level held? A non-specific scientific indication selected on the basis of traditional use evidence, or a specific indication supported by only observational data, are mismatches the TGA will identify in a compliance review. Getting the evidence-indication alignment right before listing is considerably less disruptive than correcting it after a compliance request arrives.

Across TGA, FTC, and ACCC frameworks, the underlying logic is consistent. The jurisdictions differ in their specific pathways, terminology, and enforcement mechanisms — but the principle holds. A claim needs evidence adequate to the message it conveys, and for AUST L products specifically, the TGA's four-level framework gives Australian brands the clearest roadmap available for working out what that means in practice.

Frequently asked questions

What are the evidence requirements for an AUST L listed medicine?

Evidence requirements for an AUST L listed medicine depend on the type and specificity of the indication selected. The TGA's Evidence Guidelines v4.0 map four evidence levels to four claim types: non-specific traditional indications require documented traditional use within a recognised paradigm; non-specific scientific indications can be supported by observational data; specific scientific indications require well-designed human studies matched to the specific indication, dose, and target population; and establishment claims such as "clinically proven" sit outside the AUST L framework entirely and are governed by the Therapeutic Goods Advertising Code. The sponsor must hold adequate evidence at the time of listing and produce it if the TGA requests it in a compliance review.

What is the difference between AUST L and AUST R evidence requirements?

AUST L listed medicines do not require pre-market efficacy assessment by the TGA — the sponsor self-certifies that they hold adequate evidence at time of listing, and the TGA may audit that evidence post-market in a compliance review. AUST L indications are limited to low-level permitted indications from the Permissible Indications Determination. AUST R registered medicines and AUST L(A) assessed listed medicines undergo TGA pre-market evaluation of efficacy evidence, allowing access to higher-level indications. The evidence standard for AUST R is substantially higher, typically requiring full clinical trial data. The assessed listed AUST L(A) pathway sits between the two, requiring pre-market efficacy assessment without the full safety and quality data requirements of AUST R.

What is the FTC's competent and reliable scientific evidence standard?

The FTC requires that health claims for dietary supplements and other health products be supported by tests, analyses, research, or studies conducted in an objective manner by experts in the relevant field, using procedures generally accepted in the profession to yield accurate and reliable results. As a general rule, this means well-designed, randomised, controlled human clinical trials. Animal and in vitro studies alone are not sufficient, and consumer testimonials do not substitute for independent scientific evidence.

Can traditional use evidence substantiate an AUST L indication in Australia?

Yes, for non-specific traditional indications under the TGA's listed medicines framework. Traditional use evidence can support claims that fall within a recognised traditional medicine paradigm such as Western herbal medicine, Chinese medicine, or Ayurveda, and that describe general health maintenance rather than specific clinical outcomes. The evidence must relate to an ingredient sufficiently identical to the one described in the traditional literature, at a comparable dose and route of administration. Importantly, the TGA's traditional use pathway does not apply in the US, where the FTC requires competent and reliable scientific evidence for all health claims regardless of traditional use history.

Does ingredient-level evidence substantiate a claim on an AUST L product?

Not automatically. Ingredient supplier dossiers are a valuable starting point for building an AUST L evidence pack, but they do not substitute for product-level substantiation where the product delivers a different dose, formulation, or target population than the studies in the dossier. The TGA assesses whether the evidence maps to the specific product as listed — including its dose and the consumer it is marketed to. Ingredient-level evidence with material differences in dose or population requires justification for extrapolation in the evidence package.

What is the difference between a structure/function claim and an establishment claim for AUST L purposes?

A structure/function claim describes how an ingredient or product affects the body's structure or function, for example "supports healthy immune function." An establishment claim asserts that something has been clinically demonstrated, for example "clinically proven to boost immunity." For AUST L sponsors, establishment claims are not permitted indications and sit outside the ARTG entry framework entirely — they are governed by the Therapeutic Goods Advertising Code instead. The NARB's May 2026 Tru Niagen ruling confirmed that the substantiation standard for any claim depends on the message it conveys to consumers, not the advertiser's regulatory classification.

What happens during a TGA AUST L compliance review?

The TGA may conduct a compliance review of an AUST L listed medicine at any time, either as part of a random post-market audit or in response to a complaint. In a review, the TGA requests the sponsor's evidence file and assesses whether the evidence held adequately supports each indication in the ARTG entry, whether the product is manufactured to GMP standards, and whether advertising claims are consistent with the ARTG entry and the Therapeutic Goods Advertising Code. If the evidence is found to be inadequate, the TGA can require the sponsor to remove or modify indications, take the product off the market, or in serious cases pursue enforcement action. Sponsors must hold evidence at the time of listing — not assembled after a review request arrives.

How Parallaxis helps

Getting AUST L substantiation right means more than assembling a folder of studies. It means selecting the right indication level for the evidence you hold, mapping each study against the TGA's filter criteria for relevance and quality, identifying gaps before they appear in a compliance review, and producing a filing-ready evidence package that holds up under scrutiny. Parallaxis builds AUST L evidence packs aligned to TGA Evidence Guidelines v4.0 and the Permissible Indications Determination (No. 1) 2025, covering indication classification, systematic literature search, evidence filtering, and a complete substantiation document. If you want to understand where your current evidence sits before you list — or before the TGA asks — start with the AUST L Evidence Readiness Assessment at assess.parallaxis.com.au, or get in touch to talk through what a full evidence pack would involve for your product.

‍

AUST L Evidence Requirements: How Much Is "Enough" Depends on the Claim